Spots Global Cancer Trial Database for De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Official Title: De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects
Study ID: NCT00328770
Conditions
Interventions
Study Description
Brief Summary: This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
Detailed Description: A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver transplant and were included in the study. Immunosuppression included de novo sirolimus, low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no steroids.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alberta, Edmonton, Alberta, Canada
Contact Details
Name: Norman M Kneteman, MD
Affiliation: University of Alberta
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
